mRNA-based influenza vaccine expands the B cell response breadth in humans
Hanover Matz(Washington University in St. Louis), Ali H. Ellebedy(Washington University in St. Louis), Garazi Peña Alzua(Icahn School of Medicine at Mount Sinai), Raffael Nachbagauer(Moderna Therapeutics (United States)), Caroline Kikawa(University of Washington Medical Center), Fangjie Han(Guangzhou University), Julian Q. Zhou(AbCellera (Canada)), Rachel M. Presti(Johns Hopkins University), Stephen Horváth(Washington University in St. Louis), Aaron J. Schmitz(Washington University in St. Louis), Kritika Dixit(Washington University in St. Louis), Lowrey Peyton(Dartmouth College), Jackson S. Turner(Washington University in St. Louis), Florian Krammer(Semmelweis University), Robert Paris(GlaxoSmithKline (United States)), Michael K. Klebert(Washington University in St. Louis), Jesse D. Bloom(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Hunter K. Keplinger(Washington University in St. Louis), Jiwon Lee(Dartmouth College), Nina H. Lin(Moderna Therapeutics (United States)), Tae-Geun Yu(Dartmouth College), Robert Hoelzl(Icahn School of Medicine at Mount Sinai), Mark J. Hoegger(Mallinckrodt (United States)), William D. Middleton(Mallinckrodt (United States)), Ariana Ghez Farrell(University of Washington), Anders Madsen(Haukeland University Hospital), Benjamin S. Strnad(Mallinckrodt (United States))
Cited by 0
Related Papers
Influenza
|Nature Reviews Disease Primers|2018|1.5k
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
|Nature Medicine|2021|1k
Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization
|Cell Host & Microbe|2021|851
Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine
|New England Journal of Medicine|2021|803